Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine

J Infect Dis. 2022 Nov 28;226(11):1959-1963. doi: 10.1093/infdis/jiac272.

Abstract

Background: An effective dengue vaccine should ideally induce broadly neutralizing antibody (nAb) responses against all 4 dengue virus (DENV) serotypes.

Methods: We characterized the specificity and breadth of the nAb response to TAK-003, a live-attenuated tetravalent dengue vaccine, in serum samples from phase 2 and 3 clinical trials.

Results: Microneutralization tests using postvaccination serum showed comparable neutralization against diverse DENV-1-4 genotypes. Reporter virus particle neutralization assays after depletion of anti-DENV-2 nAbs demonstrated that the nAb response to DENV-1, -3, and -4 comprises both type-specific (TS) and cross-reactive (CR) nAbs.

Conclusions: Therefore, TAK-003 induces broad tetravalent TS and CR nAb responses.

Keywords: TAK-003; dengue vaccine; dengue virus; neutralizing antibody response; type-specific.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Dengue Vaccines*
  • Dengue Virus*
  • Dengue*
  • Humans
  • Vaccines, Attenuated
  • Vaccines, Combined

Substances

  • Antibodies, Neutralizing
  • Dengue Vaccines
  • Vaccines, Combined
  • Antibodies, Viral
  • Vaccines, Attenuated